Tuesday, November 12, 2013, 11:00 a.m. - 11:55 a.m., Room 405
China, and its neighboring countries, represent a significant private sector opportunity for new vaccines. Chinese vaccine companies, working in partnership with other vaccine companies, are developing important medicine that addresses the specific unmet medical needs in China and other Asian markets. These collaborations bring novel vaccine technology into the Chinese research institutions while offering small and large Western vaccine companies the opportunity to bring new products to the growing Chinese private sector. Vaccines that protect against pneumococcal disease, HPV, influenza and RSV are in development or clinical trials. The panelists for this topic will discuss successful partnerships designed to solve key public health issues in China and other emerging markets as well as examine the availability of novel technologies, sustainable production capacity and innovation, and the potential impact on Chinese vaccine companies and their partners.
- Phyllis Arthur, Senior Director, Vaccines, Immunotherapeutics & Diagnostics Policy, BIO
- Li Shi, PhD, CEO, Shanghai Zerun Biotech
- Jean-Denis Shu, MD, Medical Director, Sanofi Pasteur, China
- Sean Du, PhD, Chief Operating Officer, Altravax